<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848652</url>
  </required_header>
  <id_info>
    <org_study_id>RB 12.032 - MYLY</org_study_id>
    <nct_id>NCT01848652</nct_id>
  </id_info>
  <brief_title>Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.</brief_title>
  <acronym>MYLY</acronym>
  <official_title>Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol is to assess the overall response rate (complete response and partial response)
      of treatment with non-pegylated liposomal doxorubicin at a dose of 50 mg / m² in combination
      with dexamethasone in immunocompetent adult patients with primary brain lymphoma large
      B-cell refractory or relapsed after first-line treatment MTXHD and high-dose cytarabine,
      excluding strict eye lymphomas.

      This is a Phase II, open, prospective, multicenter, non-comparative with direct individual
      benefit.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Answer at treatment</measure>
    <time_frame>after 2 cycles of treatment (84 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Answer, whether complete or partial, according to the International Primary CNS Lymphoma Collaborative Group (IPCG) (ASH 2004) after two cycles of treatment (4 infusions MYOCET ®).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance at treatment</measure>
    <time_frame>after each cycle and until the end of follow</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerance, assessed according to the criteria of the National Cancer Institute (NCI)-Common Toxicity Criteria (CTC) version (version 4.03) after administration of each cycle, overall survival, progression-free and disease-free event for complete responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cerebral Lymphoma B Cell Refractory</condition>
  <arm_group>
    <arm_group_label>MYOCET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion of MYOCET</intervention_name>
    <arm_group_label>MYOCET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with cerebral lymphoma B cell refractory or relapsed within 12 months after
             first-line chemotherapy with high-dose methotrexate (1.5 g / m²) and high dose
             cytarabine (2g / m²) and / or radiotherapy or autologous, or patient with an
             indication against these treatments.

        Refractory disease is defined by the absence of objective response to treatment or relapse
        within 3 months of it. A relapse is defined as disease progression after obtaining a
        complete or partial response.

          -  Age greater than or equal to 18 years

          -  Performance Index less than 4

          -  Illness measured by CT or MRI

          -  Hematologic adequate: neutrophils&gt; 1.5 x 106 / L, platelets&gt; 100x106 / L

          -  Adequate hepatic function: ALT / AST and bilirubin less than the upper limit of the
             normal laboratory

          -  Adequate renal function: creatinine clearance greater than 60 ml / min

          -  adequate cardiac function measured by ejection fraction of the left ventricle&gt; 50% by
             echocardiography

          -  Informed consent signed

          -  Negative pregnancy test for women of childbearing age

          -  Able to understand the arrangements for monitoring the study and to comply

          -  Corticosteroids are only accepted during the first cycle

        Exclusion Criteria:

          -  Patients with immunosuppression from any cause (HIV, history of transplantation,
             immunosuppressive treatments ...)

          -  Prior treatment MYOCET ® or other anthracycline

          -  Active infection

          -  Surgery large (more than 3 days hospitalization) within 28 days before enrollment in
             the study, except for a diagnostic neurosurgical

          -  Hypersensitivity to any component of the treatment

          -  Contraindications to the administration of MYOCET ® and / or dexamethasone
             Participation in a clinical trial within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian TEMPESCUL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian TEMPESCUL, Dr</last_name>
    <phone>02 98 22 33 95</phone>
    <email>adrian.tempescul@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud - Hôpital Haut-Levêque Centre François Magendie</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krimo BOUABDALLAH, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Pierre MOLES-MOREAU, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian TEMPESCUL, Dr</last_name>
      <phone>02 98 22 33 95</phone>
      <email>adrian.tempescul@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>franck MORSCHHAUSER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline HOUILLER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin - Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole SOUSSAIN, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel GYAN, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>May 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral lymphoma B cell refractory</keyword>
  <keyword>Myocet</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
